What is SYRE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SYRE.

Stock Ratings / Health Care / SYRE / options

MDGL (38) PTGX (65) TGTX (63) BMRN (74) ⌘ Pro Terminal →

Spyre Therapeutics Inc. (SYRE) Options Positioning, Max Pain & Unusual Sweeps

$96.56 -2.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $95.96

Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $10.08B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SYRE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Spyre Therapeutics Inc. (NASDAQ: SYRE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $96.56 (-2.42% 1D, market cap $10.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, SYRE ranks #203 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SYRE compare to MDGL and PTGX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SYRE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.0%. By comparison, MDGL (Madrigal Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B) and PTGX (Protagonist Therapeutics Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SYRE?

▼

Per SYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636282), Spyre Therapeutics Inc. generated $586.8M in revenue (+0.5% YoY), -$155.2M in net income, and -$169.3M in free cash flow against $777.8M in total assets and $28.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $95.95 (-0.63%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SYRE)Realized 20D OHLCV Swing Band: ±9.6%

Deterministic 5-Pillar Attribution (55/100 Composite)

🔍 WHY SYRE SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (31% of score)

20D Institutional Volume Accumulation (±9.6% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (29% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 0% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$78.63+18.2% Next Q

Q2 (-2Q)

Grade C-$92.95+7.3% Next Q

Q3 (-1Q)

Grade C-$99.75-3.2% Next Q

Current

Grade D+$96.56-0.5% Hist 90D α

Trajectory: D (47) → D+ (55)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SYRE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, SYRE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($89.54) or 200D SMA ($74.19) invalidates the momentum regime and cuts Target Base ($95.26) toward Bear Floor ($74.30).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SYRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SYRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 55%NO 45%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.6%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SYRE)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SYRE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SYRE)

✓Walkthrough of SYRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SYRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +39.68%⚡ TESTING RESISTANCE

2026-11-03O $98.96H $98.96L $96.56C $96.56VOL 661.2K

RES: $99.64SUP: $78.53SMA50: $89.54SMA200: $74.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SYRE Butterfly Map → + Track SYRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

15.7%/yr Implied 5Y Growth

vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SYRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SYRE)

Health Care Rank #203 of 1016 ⚔️ MDGL vs SYRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SYRE vs. MDGL, PTGX, TGTX, BMRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Spyre Therapeutics Inc. (SYRE) ranks #203 by composite RQD confidence (55/100, grade D+) and #109 by equity capitalization ($10.08B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with SYRE at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SYRE ACTIVE Spyre Therapeutics Inc.	D+	55/100	—	—	-20.0%	-2.42%	$10.08B	Benchmark Subject
MDGL Madrigal Pharmaceuticals Inc.	D-	38/100	—	—	-29.7%	-0.31%	$9.94B	/mdgl-vs-syre →
PTGX Protagonist Therapeutics Inc.	C	65/100	—	—	-16.7%	+0.35%	$9.37B	/ptgx-vs-syre →
TGTX TG Therapeutics Inc.	C	63/100	19.9x	83.7%	12.0%	+5.34%	$9.36B	/tgtx-vs-syre →
BMRN BioMarin Pharmaceutical Inc.	B	74/100	31.9x	77.7%	6.0%	+1.77%	$11.33B	/bmrn-vs-syre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001636282

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spyre Therapeutics Inc. (SYRE) reported GAAP revenue of $586.8M (+0.5% vs. FY2024 revenue of $584.0M , and +66127.3% cumulative change since FY2023) , GAAP net income of -$155.2M, operating cash flow of -$169.3M, and free cash flow of -$169.3M (-7.5% YoY). On the balance sheet, SYRE closed FY2025 with $777.8M in total assets against $28.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$586.8M	-$155.2M	-$169.3M	-$169.3M	$777.8M	$28.1M
FY2024 (FY)	2024-12-31	$584.0M	-$208.0M	-$157.4M	-$157.4M	$608.5M	$40.8M
FY2023 (FY)	2023-12-31	$886.0K	-$338.8M	-$99.9M	-$99.9M	$5.68B	$1.33B

3. SYRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SYRE compare to MDGL and PTGX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SYRE?

Where is SYRE trading relative to its 50-day, 200-day, and 52-week technical levels?

SYRE last traded at $96.56 (-2.42% on volume of 661,175 shares), positioning the stock +7.84% above its 50-day simple moving average ($89.54) and +30.15% above its 200-day simple moving average ($74.19). Across its 52-week range of $21.15 to $110.18, SYRE sits at the 84.7% percentile with a 14-day RSI of 57.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.6% ($87.29 to $105.83).

Direct Sub-Reports: SYRE RQD Cockpit SYRE 12M Forecast SYRE Earnings & Move SYRE Dividends & DRIP SYRE Insiders & 13F SYRE Whale Options SYRE Profit Sankey SYRE News & Why

ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SYRE — Spyre Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:16:26Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

SYRE holds an RQD Score of 55, letter grade D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental Cash Engine: 5 / 20. ROIC is -20% and FCF yield is -1.64%. This is the weakest pillar and the main reason the overall score is low. For a prospective investor, the company is not currently generating returns on invested capital or positive free cash flow, so value depends on future outcomes not yet visible in reported results.
Whale 13F Flow: 17 / 20. this pillar reflects institutional accumulation and options positioning. It is the strongest pillar and signals that large holders are positioned constructively, though the source does not itemize holders (see Analyst View section).
Insider Conviction: 6 / 20. this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider conviction signals in the source data.
Macro Regime Fit: 11 / 20. beta is 0.89 with sector sensitivity noted. The stock's sensitivity to broad market moves is below 1.0, but the score is mid-range, indicating the regime fit is neither strongly supportive nor strongly adverse.
Forensic Balance Sheet: 16 / 20. Altman Z is 26, Piotroski F is 5/9, and Debt/Equity is 0.04. Leverage is minimal and solvency metrics are strong, which partially offsets the weak cash engine.

Investor implications: the upside case rests on institutional positioning and a clean balance sheet giving runway, while valuation tradeoffs are significant given negative EPS (-1.49 TTM) and a forward P/E of 22 against a market cap of $10.33B. The rating's "Trim" verdict reflects that fundamentals currently do not support the price on cash-flow metrics.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Reported revenue is — for FY 2025 and FY 2024, and $0.9M for FY 2023, . Specifics of how the company monetizes its activities are —

The company reported operating losses across all three periods, with gross, operating, and net margins each shown as 0% in the market data. Per the market data, ROIC is -20%. The Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Debt fell from $1.33B (FY 2023) to $28.1M (FY 2025), and Debt/Equity is 0.04 per the RQD forensic pillar.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Institutional accumulation and options positioning score 17/20 while Debt/Equity of 0.04 and an Altman Z of 26 indicate minimal balance-sheet stress. With Fundamental Cash Engine at 5/20 (ROIC -20.0%, FCF yield -1.64%) and Institutional Whale Flow at 17/20, sustained execution supports upside toward the top of the $21.15 – $110.18 52-week range.
🐻 Primary Bear Case: ROIC of -20%, FCF yield of -1.64%, and a pending public offering signal that current operations are not self-funding and may dilute shareholders. Investors must weigh current valuation against — operating margins and a 0.89 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links, no supply-chain designation, and no proprietary signals. Sector correlations and second-order bottlenecks are — The only related catalyst is the public offering noted in the news feed, which may dilute existing holders; the source does not quantify the offering size or terms.

Key Question #1: What are the terms, size, and proceeds of the proposed public offering, and how would it affect share count and dilution?
Key Question #2: What products or clinical programs drive the company, and what is their development timeline?
Key Question #3: What explains the gap between the negative EPS (-1.49 TTM) and the forward P/E of 22?

SYRE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Spyre Therapeutics Inc. (SYRE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SYRE Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 20h ago

Spyre Therapeutics stock falls on public offering launch

Yahoo Finance report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 23h ago

Why is Spyre Therapeutics stock sliding today?

Investing.com report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview

Yahoo Finance report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Spyre Therapeutics, Inc. Estimates – NASDAQ:SYRE

TradingView report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

www.marketscreener.com report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Seeking Alpha report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TIKR.com • 1d ago

Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market

TIKR.com report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A proposed stock sale could help Spyre advance a new drug program into late-stage development.

Stock Titan report covering Spyre Therapeutics Inc. (SYRE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SYRE Bull vs. Bear Conversation Board — What's Your Call at $96.56?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SYRE 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $119.73 (+24.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 17/20 while Debt/Equity of 0.04 and an Altman Z of 26 indicate minimal balance

Here is why I am bullish on SYRE here at $96.56: Institutional accumulation and options positioning score 17/20 while Debt/Equity of 0.04 and an Altman Z of 26 indicate minimal balance-sheet stress.. Compare SYRE's 0.0% operating margin and -20.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $91.73 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SYRE's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH 🎯 Target: $83.04 (-14.0%)

Spot @ $96.56

ROIC of -20%, FCF yield of -1.64%, and a pending public offering signal that current operations are not self-funding and may dilute sha

Careful chasing SYRE at $96.56. ROIC of -20%, FCF yield of -1.64%, and a pending public offering signal that current operations are not self-funding and may dilute shareholders.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $83.04 on multiple compression.